EP Patent

EP1836320A2 — Compositions for modulation of parp and methods for screening for same

Assigned to Arqule Inc · Expires 2007-09-26 · 19y expired

What this patent protects

The present invention relates a method for screening for a PARP activator. The screening method comprises the step of assessing the PARP-activating effect of a test compound, using cells, cell lysate, or purified PARP. The present invention also provides a method for the treatmen…

USPTO Abstract

The present invention relates a method for screening for a PARP activator. The screening method comprises the step of assessing the PARP-activating effect of a test compound, using cells, cell lysate, or purified PARP. The present invention also provides a method for the treatment of cancers. The treatment method comprises administering to the subject a therapeutically effective amount of a PARP activator.

Drugs covered by this patent

Patent Metadata

Patent number
EP1836320A2
Jurisdiction
EP
Classification
Expires
2007-09-26
Drug substance claim
No
Drug product claim
No
Assignee
Arqule Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.